The multiple myeloma armamentarium is large and getting larger. That makes treatment choices complex and the cost of ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients ...

The following is a summary of “Retrospective analysis of treatment discontinuation in minimal residual disease negative multiple myeloma,” published in the March 2025 issue of International Journal of ...

Final data from the phase 3 ALCYONE trial support frontline use of daratumumab-based therapy for patients with ...

1 Multiple myeloma originates in blood plasma cells ... the use of blood-based monitoring to detect minimal residual disease, which refers to the small number of cancer cells that remain ...

Also, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted unanimously in April 2024 to accept MRD as a clinical endpoint for accelerated approval of new multiple myeloma therapies ...

Welcome to the Adaptive Biotechnologies first-quarter 2025 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the ...

Detailed price information for Telo Genomics Corp (TDSGF) from The Globe and Mail including charting and trades.